Gomis et al., "Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM
trial," JAMA, vol.
Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM
Because these agents target postprandial hyperglycemia, their cardioprotective effect may be similar to other compounds which reduce postmeal glucose excursions such as acarbose in the STOP-NIDDM
Chiasson et al., "Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM
trial," Diabetes, vol.
(16.) Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M for The STOP-NIDDM
Trial Research Group.
trial was one of several pointing to the importance of post-prandial glucose values, which have until recently received less attention than fasting glucose.
was one of several recent studies pointing to the importance of postprandial glucose values, which have until recently received less attention than fasting glucose.
was an international randomized trial in which 1,368 patients with impaired glucose tolerance were randomized to acarbose--an alpha-glucosidase inhibitor that delays glucose absorption--or placebo.
The impetus for MERIA lay in the favorable results of the Study to Prevent Non-Insulin Dependent Diabetes Mellitus (STOP-NIDDM
) trial, which showed that acarbose lowered the rate of cardiovascular events in patients with insulin resistance (JAMA 290:486-94, 2003).
Zeymer focused on a secondary end point of the STOP-NIDDM
(Study to Prevent Non-Insulin-Dependent Diabetes Mellitus) trial.
Assessment of the effects of therapy aimed at lowering PPG in the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM
) trial (19) indicated that treatment with acarbose (100 mg administered 3 times per day) was associated with decreased risk for silent MI vs placebo in patients with impaired glucose tolerance.
He presented a new secondary analysis of data from the Study to Prevent Noninsulin-Dependent Diabetes Mellitus (STOP-NIDDM